25 XP   0   0   10

Seelos Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Seelos Therapeutics Inc together

PenkeI guess you are interested in Seelos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Seelos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Seelos Therapeutics Inc

I send you an email if I find something interesting about Seelos Therapeutics Inc.

Quick analysis of Seelos Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Seelos Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.45
Expected worth in 1 year
$-4.12
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-1.67
Return On Investment
-500.4%

For what price can you sell your share?

Current Price per Share
$0.33
Expected price per share
$0 - $0.7071
How sure are you?
50%

1. Valuation of Seelos Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.33

Intrinsic Value Per Share

$-12.50 - $-12.31

Total Value Per Share

$-14.95 - $-14.76

2. Growth of Seelos Therapeutics Inc (5 min.)




Is Seelos Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$33.5m$17.2m-$50.2m-152.5%

How much money is Seelos Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.4m-$19m$8.6m82.6%
Net Profit Margin-2,290.6%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Seelos Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#984 / 1016

Most Revenue
#549 / 1016

Most Profit
#564 / 1016

Most Efficient
#864 / 1016

What can you expect buying and holding a share of Seelos Therapeutics Inc? (5 min.)

Welcome investor! Seelos Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Seelos Therapeutics Inc.

What can you expect buying and holding a share of Seelos Therapeutics Inc?

First you should know what it really means to hold a share of Seelos Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Seelos Therapeutics Inc is $0.3345. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Seelos Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Seelos Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.45. Based on the TTM, the Book Value Change Per Share is $-0.42 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Seelos Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.40-119.2%-0.69-207.0%-0.47-140.6%-0.45-134.2%-0.33-98.3%
Usd Book Value Change Per Share-0.23-67.7%-0.42-125.1%-0.33-99.2%-0.13-39.4%-0.08-24.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.23-67.7%-0.42-125.1%-0.33-99.2%-0.13-39.4%-0.08-24.3%
Usd Price Per Share1.39-0.87-0.81-1.51-1.35-
Price to Earnings Ratio-0.87--0.28--0.99--2.10--1.83-
Price-to-Total Gains Ratio-6.14--1.89--4.35-11.29-23.12-
Price to Book Ratio-0.57--0.36-4.44--320.74--158.75-
Price-to-Total Gains Ratio-6.14--1.89--4.35-11.29-23.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.3345
Number of shares2989
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.42-0.13
Usd Total Gains Per Share-0.42-0.13
Gains per Quarter (2989 shares)-1,250.77-394.17
Gains per Year (2989 shares)-5,003.08-1,576.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-5003-50130-1577-1587
20-10006-100160-3153-3164
30-15009-150190-4730-4741
40-20012-200220-6307-6318
50-25015-250250-7883-7895
60-30018-300280-9460-9472
70-35022-350310-11037-11049
80-40025-400340-12613-12626
90-45028-450370-14190-14203
100-50031-500400-15767-15780

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.037.00.07.5%5.0101.00.04.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%16.024.00.040.0%38.067.01.035.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%2.00.0104.01.9%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%8.012.00.040.0%16.024.00.040.0%38.067.01.035.8%

Fundamentals of Seelos Therapeutics Inc

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-04-12 18:02:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Seelos Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Seelos Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -835.1% means that $-8.35 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Seelos Therapeutics Inc:

  • The MRQ is -835.1%. The company is making a huge loss. -2
  • The TTM is -2,290.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-835.1%TTM-2,290.6%+1,455.6%
TTM-2,290.6%YOY--2,290.6%
TTM-2,290.6%5Y-702.6%-1,588.0%
5Y-702.6%10Y-448.1%-254.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-835.1%-199.6%-635.5%
TTM-2,290.6%-213.0%-2,077.6%
YOY--279.3%+279.3%
5Y-702.6%-438.4%-264.2%
10Y-448.1%-605.5%+157.4%
1.1.2. Return on Assets

Shows how efficient Seelos Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • -100.6% Return on Assets means that Seelos Therapeutics Inc generated $-1.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Seelos Therapeutics Inc:

  • The MRQ is -100.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -63.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-100.6%TTM-63.2%-37.4%
TTM-63.2%YOY-49.5%-13.8%
TTM-63.2%5Y-56.6%-6.6%
5Y-56.6%10Y-41.1%-15.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-100.6%-13.5%-87.1%
TTM-63.2%-12.9%-50.3%
YOY-49.5%-11.8%-37.7%
5Y-56.6%-14.1%-42.5%
10Y-41.1%-16.0%-25.1%
1.1.3. Return on Equity

Shows how efficient Seelos Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Seelos Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Seelos Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-97.1%+97.1%
TTM-5Y-113.0%+113.0%
5Y-113.0%10Y-75.3%-37.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-97.1%-15.1%-82.0%
5Y-113.0%-19.9%-93.1%
10Y-75.3%-20.9%-54.4%

1.2. Operating Efficiency of Seelos Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Seelos Therapeutics Inc is operating .

  • Measures how much profit Seelos Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,226.8% means the company generated $-12.27  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Seelos Therapeutics Inc:

  • The MRQ is -1,226.8%. The company is operating very inefficient. -2
  • The TTM is -2,168.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,226.8%TTM-2,168.7%+942.0%
TTM-2,168.7%YOY--2,168.7%
TTM-2,168.7%5Y-694.0%-1,474.7%
5Y-694.0%10Y-553.2%-140.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,226.8%-295.1%-931.7%
TTM-2,168.7%-225.8%-1,942.9%
YOY--288.4%+288.4%
5Y-694.0%-477.4%-216.6%
10Y-553.2%-625.6%+72.4%
1.2.2. Operating Ratio

Measures how efficient Seelos Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 13.27 means that the operating costs are $13.27 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Seelos Therapeutics Inc:

  • The MRQ is 13.268. The company is inefficient in keeping operating costs low. -1
  • The TTM is 22.264. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.268TTM22.264-8.996
TTM22.264YOY-+22.264
TTM22.2645Y7.055+15.209
5Y7.05510Y5.930+1.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.2683.090+10.178
TTM22.2643.264+19.000
YOY-3.783-3.783
5Y7.0555.679+1.376
10Y5.9307.894-1.964

1.3. Liquidity of Seelos Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Seelos Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.14 means the company has $0.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Seelos Therapeutics Inc:

  • The MRQ is 0.139. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.282. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.139TTM0.282-0.143
TTM0.282YOY3.332-3.050
TTM0.2825Y3.333-3.052
5Y3.33310Y3.125+0.209
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1393.914-3.775
TTM0.2824.220-3.938
YOY3.3325.388-2.056
5Y3.3336.045-2.712
10Y3.1256.406-3.281
1.3.2. Quick Ratio

Measures if Seelos Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.10 means the company can pay off $0.10 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Seelos Therapeutics Inc:

  • The MRQ is 0.097. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.167. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.097TTM0.167-0.070
TTM0.167YOY2.732-2.566
TTM0.1675Y3.004-2.837
5Y3.00410Y2.879+0.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0973.572-3.475
TTM0.1673.998-3.831
YOY2.7325.390-2.658
5Y3.0045.969-2.965
10Y2.8796.287-3.408

1.4. Solvency of Seelos Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Seelos Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Seelos Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 7.18 means that Seelos Therapeutics Inc assets are financed with 718.5% credit (debt) and the remaining percentage (100% - 718.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Seelos Therapeutics Inc:

  • The MRQ is 7.185. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 4.980. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ7.185TTM4.980+2.205
TTM4.980YOY0.782+4.197
TTM4.9805Y1.440+3.539
5Y1.44010Y1.224+0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1850.336+6.849
TTM4.9800.334+4.646
YOY0.7820.269+0.513
5Y1.4400.366+1.074
10Y1.2240.390+0.834
1.4.2. Debt to Equity Ratio

Measures if Seelos Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Seelos Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.425-1.425
TTM-5Y1.010-1.010
5Y1.01010Y1.227-0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.396-0.396
YOY1.4250.335+1.090
5Y1.0100.434+0.576
10Y1.2270.465+0.762

2. Market Valuation of Seelos Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Seelos Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Seelos Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.87 means the investor is paying $-0.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Seelos Therapeutics Inc:

  • The EOD is -0.210. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.872. Based on the earnings, the company is expensive. -2
  • The TTM is -0.282. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.210MRQ-0.872+0.662
MRQ-0.872TTM-0.282-0.590
TTM-0.282YOY-0.988+0.707
TTM-0.2825Y-2.105+1.823
5Y-2.10510Y-1.830-0.274
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.210-2.259+2.049
MRQ-0.872-2.569+1.697
TTM-0.282-2.664+2.382
YOY-0.988-4.120+3.132
5Y-2.105-6.258+4.153
10Y-1.830-6.171+4.341
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Seelos Therapeutics Inc:

  • The EOD is -0.599. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.488. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.879. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.599MRQ-2.488+1.889
MRQ-2.488TTM-0.879-1.608
TTM-0.879YOY-1.210+0.330
TTM-0.8795Y-2.510+1.630
5Y-2.51010Y-2.162-0.348
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.599-2.924+2.325
MRQ-2.488-3.246+0.758
TTM-0.879-3.488+2.609
YOY-1.210-5.620+4.410
5Y-2.510-8.315+5.805
10Y-2.162-8.826+6.664
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Seelos Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.57 means the investor is paying $-0.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Seelos Therapeutics Inc:

  • The EOD is -0.137. Based on the equity, the company is expensive. -2
  • The MRQ is -0.567. Based on the equity, the company is expensive. -2
  • The TTM is -0.364. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.137MRQ-0.567+0.431
MRQ-0.567TTM-0.364-0.204
TTM-0.364YOY4.440-4.804
TTM-0.3645Y-320.737+320.373
5Y-320.73710Y-158.750-161.987
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.1371.851-1.988
MRQ-0.5672.090-2.657
TTM-0.3642.095-2.459
YOY4.4402.844+1.596
5Y-320.7373.466-324.203
10Y-158.7503.815-162.565
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Seelos Therapeutics Inc.

3.1. Institutions holding Seelos Therapeutics Inc

Institutions are holding 21.985% of the shares of Seelos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Mirae Asset Global Investments (Korea) Co Ltd2.220.0009303714273725912.7513
2023-12-31Vanguard Group Inc2.07502838782838780
2023-12-31Balyasny Asset Management LLC1.93530.00072647542647540
2023-12-31WEALTH EFFECTS LLC1.67090.119522859310843090.2358
2023-12-31AdvisorShares Investments, LLC1.32490.059181259160551775.3091
2023-12-31Gendell Jeffrey L0.81590.0084111615-113182-50.3485
2023-12-31Morgan Stanley - Brokerage Accounts0.512907016353585323.2296
2023-12-31Modera Wealth Management, LLC0.50970.001669728697280
2023-12-31BlackRock Inc0.4091055964-496-0.8785
2023-12-31Lynwood Capital Management Inc.0.29240.244840000400000
2023-12-31Strategic Family Wealth Counselors, L.L.C.0.21940.01753001025001499.1216
2023-09-30Envestnet Asset Management Inc0.0073030000300000
2023-12-31Geode Capital Management, LLC0.2145029343-11044-27.3454
2023-12-31Two Sigma Investments LLC0.18450.000125246252460
2023-12-31State Street Corporation0.0946012948-164-1.2508
2023-09-30Hudson Bay Capital Management LP0.0024010000100000
2023-12-31Group One Trading, LP0.066309071-339-3.6026
2023-12-31Advisor Group Holdings, Inc.0.063908746-12715-59.247
2023-12-31Tower Research Capital LLC0.03860.0001528052800
2023-12-31Carmichael Hill & Associates Inc0.03650.002950003967384.0271
Total 12.69410.45551775312+1216205+68.5%

3.2. Funds holding Seelos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28AdvisorShares Psychedelics ETF3.38213.702646269400
2024-02-29Horizons Psychedelic Stock ETF1.91014.2173261318-41580-13.7274
2023-09-30BlackRock Extended Mkt Composite0.06080.000324937400
2024-02-29Vanguard Total Stock Mkt Idx Inv1.6439022489300
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.01780.000173139-3283658-97.8212
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.40480.00015537300
2024-02-29Fidelity Extended Market Index0.21220.000129032-141-0.4833
2024-03-31BlackRock Extended Equity Market K0.0530725230.0414
2024-02-29Fidelity Total Market Index0.0480657100
2024-02-29Fidelity Series Total Market Index0.03860527500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.02510.00013427-2-0.0583
2023-12-31Northern Trust Extended Eq Market Idx0.02510.00013427-2-0.0583
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.02290.0001313700
2024-02-29Fidelity Nasdaq Composite Index0.02060282300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01840.0001251950.1989
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.01780243800
2024-02-29Spartan Total Market Index Pool E0.0160219500
2024-03-31BlackRock U.S. Equity Market F0.012401702160.949
2024-02-29Spartan Extended Market Index Pool E0.01240.000116921419.0909
2024-02-29Vanguard U.S. Eq Idx £ Acc0.00860117500
Total 7.95067.9211399456-3325218-237.6%

3.3. Insider Transactions

Insiders are holding 2.002% of the shares of Seelos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-06-01Daniel J O'connorBUY53318.3
2022-03-31Raj MehraBUY222225.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Seelos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.226-0.418+85%-0.332+47%-0.132-42%-0.081-64%
Book Value Per Share---2.449-2.408-2%-0.006-100%-0.286-88%-0.110-96%
Current Ratio--0.1390.282-51%3.332-96%3.333-96%3.125-96%
Debt To Asset Ratio--7.1854.980+44%0.782+819%1.440+399%1.224+487%
Debt To Equity Ratio----0%1.425-100%1.010-100%1.227-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.399-0.692+74%-0.470+18%-0.449+13%-0.329-17%
Free Cash Flow Per Share---0.140-0.437+213%-0.354+153%-0.261+87%-0.264+89%
Free Cash Flow To Equity Per Share--0.030-0.229+861%-0.387+1386%-0.035+218%-0.074+347%
Gross Profit Margin--1.0031.001+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---12.309--------
Intrinsic Value_10Y_min---12.499--------
Intrinsic Value_1Y_max---1.085--------
Intrinsic Value_1Y_min---1.246--------
Intrinsic Value_3Y_max---3.372--------
Intrinsic Value_3Y_min---3.772--------
Intrinsic Value_5Y_max---5.797--------
Intrinsic Value_5Y_min---6.309--------
Market Cap4576160.700-316%19016034.00011834403.030+61%69937798.335-73%82956808.581-77%49566032.995-62%
Net Profit Margin---8.351-22.906+174%--100%-7.026-16%-4.481-46%
Operating Margin---12.268-21.687+77%--100%-6.940-43%-5.532-55%
Operating Ratio--13.26822.264-40%-+100%7.055+88%5.930+124%
Pb Ratio-0.137+76%-0.567-0.364-36%4.440-113%-320.737+56420%-158.750+27875%
Pe Ratio-0.210+76%-0.872-0.282-68%-0.988+13%-2.105+141%-1.830+110%
Price Per Share0.335-316%1.3900.865+61%0.807+72%1.509-8%1.346+3%
Price To Free Cash Flow Ratio-0.599+76%-2.488-0.879-65%-1.210-51%-2.510+1%-2.162-13%
Price To Total Gains Ratio-1.477+76%-6.138-1.886-69%-4.353-29%11.293-154%23.116-127%
Quick Ratio--0.0970.167-42%2.732-96%3.004-97%2.879-97%
Return On Assets---1.006-0.632-37%-0.495-51%-0.566-44%-0.411-59%
Return On Equity----0%-0.9710%-1.1300%-0.7530%
Total Gains Per Share---0.226-0.418+85%-0.332+47%-0.132-42%-0.081-64%
Usd Book Value---33510000.000-32940000.000-2%17283000.000-294%10655900.000-414%5783975.000-679%
Usd Book Value Change Per Share---0.226-0.418+85%-0.332+47%-0.132-42%-0.081-64%
Usd Book Value Per Share---2.449-2.408-2%-0.006-100%-0.286-88%-0.110-96%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.399-0.692+74%-0.470+18%-0.449+13%-0.329-17%
Usd Free Cash Flow---1911000.000-5978000.000+213%-15401000.000+706%-8736450.000+357%-6199600.000+224%
Usd Free Cash Flow Per Share---0.140-0.437+213%-0.354+153%-0.261+87%-0.264+89%
Usd Free Cash Flow To Equity Per Share--0.030-0.229+861%-0.387+1386%-0.035+218%-0.074+347%
Usd Market Cap4576160.700-316%19016034.00011834403.030+61%69937798.335-73%82956808.581-77%49566032.995-62%
Usd Price Per Share0.335-316%1.3900.865+61%0.807+72%1.509-8%1.346+3%
Usd Profit---5453000.000-10424750.000+91%-19038500.000+249%-12694100.000+133%-7776125.000+43%
Usd Revenue--653000.000550750.000+19%-+100%166400.000+292%597675.000+9%
Usd Total Gains Per Share---0.226-0.418+85%-0.332+47%-0.132-42%-0.081-64%
 EOD+2 -6MRQTTM+23 -9YOY+18 -155Y+12 -2110Y+11 -22

4.2. Fundamental Score

Let's check the fundamental score of Seelos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.210
Price to Book Ratio (EOD)Between0-1-0.137
Net Profit Margin (MRQ)Greater than0-8.351
Operating Margin (MRQ)Greater than0-12.268
Quick Ratio (MRQ)Greater than10.097
Current Ratio (MRQ)Greater than10.139
Debt to Asset Ratio (MRQ)Less than17.185
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.006
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Seelos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.088
Ma 20Greater thanMa 500.492
Ma 50Greater thanMa 1000.766
Ma 100Greater thanMa 2001.088
OpenGreater thanClose0.340
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,418
Total Liabilities38,928
Total Stockholder Equity-33,510
 As reported
Total Liabilities 38,928
Total Stockholder Equity+ -33,510
Total Assets = 5,418

Assets

Total Assets5,418
Total Current Assets5,403
Long-term Assets15
Total Current Assets
Cash And Cash Equivalents 2,996
Net Receivables 763
Other Current Assets 1,644
Total Current Assets  (as reported)5,403
Total Current Assets  (calculated)5,403
+/-0
Long-term Assets
Property Plant Equipment 15
Long-term Assets  (as reported)15
Long-term Assets  (calculated)15
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities38,928
Long-term Liabilities0
Total Stockholder Equity-33,510
Total Current Liabilities
Short-term Debt 14,228
Short Long Term Debt 14,213
Accounts payable 16,403
Other Current Liabilities 8,297
Total Current Liabilities  (as reported)38,928
Total Current Liabilities  (calculated)53,141
+/- 14,213
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock10
Retained Earnings -252,626
Other Stockholders Equity 219,106
Total Stockholder Equity (as reported)-33,510
Total Stockholder Equity (calculated)-33,510
+/-0
Other
Capital Stock10
Cash and Short Term Investments 2,996
Common Stock Shares Outstanding 9,795
Current Deferred Revenue0
Liabilities and Stockholders Equity 5,418
Net Debt 11,232
Net Invested Capital -19,297
Net Working Capital -33,525
Property Plant and Equipment Gross 15
Short Long Term Debt Total 14,228



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-31
> Total Assets 
0
0
0
2,330
5,570
6,110
6,550
5,920
5,190
540
8,220
7,630
12,325
18,760
41,970
39,990
37,675
34,109
31,914
27,315
21,210
25,063
18,424
14,140
12,327
13,628
20,241
23,134
19,203
23,029
17,806
20,273
15,351
15,343
17,267
13,332
17,522
16,077
14,205
19,934
18,195
13,070
11,189
10,673
9,425
10,504
8,350
8,558
9,212
8,051
6,647
20,933
22,291
24,481
21,632
18,864
19,602
14,080
13,977
16,616
31,877
29,198
40,750
23,879
16,628
26,922
22,301
23,310
24,994
20,285
19,796
14,809
19,637
11,390
9,600
7,855
10,432
6,166
8,410
4,700
5,353
8,815
8,823
6,706
6,020
7,222
5,564
3,760
12,344
10,279
16,211
11,096
14,171
7,760
9,878
17,494
41,370
90,309
80,946
83,500
70,693
52,667
40,508
22,746
23,641
11,889
6,218
5,418
5,4186,21811,88923,64122,74640,50852,66770,69383,50080,94690,30941,37017,4949,8787,76014,17111,09616,21110,27912,3443,7605,5647,2226,0206,7068,8238,8155,3534,7008,4106,16610,4327,8559,60011,39019,63714,80919,79620,28524,99423,31022,30126,92216,62823,87940,75029,19831,87716,61613,97714,08019,60218,86421,63224,48122,29120,9336,6478,0519,2128,5588,35010,5049,42510,67311,18913,07018,19519,93414,20516,07717,52213,33217,26715,34315,35120,27317,80623,02919,20323,13420,24113,62812,32714,14018,42425,06321,21027,31531,91434,10937,67539,99041,97018,76012,3257,6308,2205405,1905,9206,5506,1105,5702,330000
   > Total Current Assets 
0
0
0
200
3,720
4,290
4,730
3,860
2,870
320
8,000
7,290
11,854
18,148
41,126
36,592
33,149
28,752
25,893
19,623
11,691
14,013
6,603
2,271
823
2,278
9,205
12,511
8,821
12,861
7,846
10,531
5,774
5,994
8,140
4,418
9,070
7,862
6,518
12,446
10,879
5,875
4,110
3,682
2,566
3,727
1,687
2,977
4,055
2,961
1,651
1,767
3,272
5,114
2,979
10,477
11,419
9,362
9,350
8,191
23,127
19,745
26,749
20,895
15,583
26,318
21,662
22,264
23,541
17,420
18,371
13,289
18,035
9,816
8,165
6,291
9,119
4,925
7,236
3,634
5,146
8,649
8,688
6,592
5,918
7,130
5,481
3,685
12,320
10,255
16,211
11,096
14,171
7,760
9,878
17,494
41,296
90,246
80,895
83,461
70,667
52,654
40,508
22,674
23,583
11,845
6,188
5,403
5,4036,18811,84523,58322,67440,50852,65470,66783,46180,89590,24641,29617,4949,8787,76014,17111,09616,21110,25512,3203,6855,4817,1305,9186,5928,6888,6495,1463,6347,2364,9259,1196,2918,1659,81618,03513,28918,37117,42023,54122,26421,66226,31815,58320,89526,74919,74523,1278,1919,3509,36211,41910,4772,9795,1143,2721,7671,6512,9614,0552,9771,6873,7272,5663,6824,1105,87510,87912,4466,5187,8629,0704,4188,1405,9945,77410,5317,84612,8618,82112,5119,2052,2788232,2716,60314,01311,69119,62325,89328,75233,14936,59241,12618,14811,8547,2908,0003202,8703,8604,7304,2903,720200000
       Cash And Cash Equivalents 
0
0
0
130
1,610
1,250
1,830
1,680
540
20
7,740
5,120
9,637
14,374
36,268
27,703
22,968
18,756
15,917
12,914
6,008
11,430
4,813
1,035
205
1,546
7,201
9,479
5,295
10,626
5,783
7,747
2,472
3,770
5,697
2,954
5,476
4,693
3,995
11,069
8,163
3,080
1,957
2,736
2,383
3,381
1,437
2,863
3,758
2,811
1,539
480
2,547
4,215
1,768
9,146
10,175
9,140
8,878
7,435
21,529
17,940
16,861
15,130
14,104
24,764
20,619
21,405
22,491
17,420
16,109
11,400
16,156
7,433
5,809
3,887
6,907
2,723
5,614
2,087
3,762
7,821
8,463
6,331
5,678
6,836
5,283
3,579
11,292
9,728
15,315
10,261
12,688
5,854
8,054
15,662
38,687
87,200
76,833
78,734
61,772
41,251
30,511
15,533
14,059
5,843
2,584
2,996
2,9962,5845,84314,05915,53330,51141,25161,77278,73476,83387,20038,68715,6628,0545,85412,68810,26115,3159,72811,2923,5795,2836,8365,6786,3318,4637,8213,7622,0875,6142,7236,9073,8875,8097,43316,15611,40016,10917,42022,49121,40520,61924,76414,10415,13016,86117,94021,5297,4358,8789,14010,1759,1461,7684,2152,5474801,5392,8113,7582,8631,4373,3812,3832,7361,9573,0808,16311,0693,9954,6935,4762,9545,6973,7702,4727,7475,78310,6265,2959,4797,2011,5462051,0354,81311,4306,00812,91415,91718,75622,96827,70336,26814,3749,6375,1207,740205401,6801,8301,2501,610130000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
1,903
715
1,587
8,087
8,885
9,084
4,579
2,266
5,017
1,081
1,007
540
540
0
1,501
1,501
1,505
504
384
1,384
2,500
1,750
1,100
500
3,000
2,000
2,000
1,000
2,500
2,500
1,000
750
750
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000007507501,0002,5002,5001,0002,0002,0003,0005001,1001,7502,5001,3843845041,5051,5011,50105405401,0071,0815,0172,2664,5799,0848,8858,0871,5877151,903000000000000
       Net Receivables 
0
0
0
0
1,280
1,460
1,740
1,290
1,350
180
180
2,000
0
0
0
0
0
0
0
0
0
155
195
198
201
169
129
48
6
0
0
0
0
0
441
582
204
811
184
184
184
0
0
0
0
0
0
0
175
0
0
1,147
584
642
346
539
745
45
221
327
892
461
3,807
678
499
681
35
59
69
49
829
678
513
664
575
519
688
687
398
530
348
179
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
793
431
221
763
7632214317930000000000000002000000179348530398687688519575664513678829496959356814996783,807461892327221457455393466425841,147001750000000184184184811204582441000006481291692011981951550000000002,0001801801,3501,2901,7401,4601,2800000
       Other Current Assets 
0
0
0
70
160
420
450
190
180
120
80
170
314
3,059
3,271
802
1,297
912
4,232
3,564
667
1,347
588
498
0
563
374
1,482
2,015
1,731
1,679
1,400
802
474
901
8
11
10
8
28
19
12
6
68
68
145
76
30
30
150
112
141
142
258
866
793
499
177
251
293
403
917
5,631
590
602
232
338
132
235
605
730
1,889
869
1,028
1,359
1,136
939
737
424
253
181
322
216
261
240
294
198
106
1,026
527
896
835
1,483
1,906
1,824
1,832
2,609
3,046
4,062
187
414
540
414
200
379
151
53
1,644
1,644531513792004145404141874,0623,0462,6091,8321,8241,9061,4838358965271,0261061982942402612163221812534247379391,1361,3591,0288691,8897306052351323382326025905,631917403293251177499793866258142141112150303076145686861219288101189014748021,4001,6791,7312,0151,48237456304985881,3476673,5644,2329121,2978023,2713,0593141708012018019045042016070000
   > Long-term Assets 
0
0
0
2,130
1,850
1,820
1,820
2,060
2,320
220
220
340
470
612
844
3,397
4,525
5,357
6,021
7,692
9,519
11,050
11,821
11,869
11,504
11,350
11,036
10,622
10,382
10,168
9,960
9,742
9,577
9,349
9,127
8,914
8,452
8,215
7,687
7,488
7,316
7,196
7,079
6,991
6,859
6,776
6,663
5,580
5,158
5,090
4,997
19,166
19,020
19,366
18,653
8,386
8,183
4,718
4,628
8,425
8,750
9,453
14,001
2,984
1,045
604
639
1,046
1,453
2,865
1,425
1,520
1,602
1,574
1,435
1,564
1,313
1,241
1,174
1,066
207
166
135
114
102
92
83
75
24
24
0
0
0
0
0
0
74
63
51
39
26
13
0
72
58
44
30
15
1530445872013263951637400000024247583921021141351662071,0661,1741,2411,3131,5641,4351,5741,6021,5201,4252,8651,4531,0466396041,0452,98414,0019,4538,7508,4254,6284,7188,1838,38618,65319,36619,02019,1664,9975,0905,1585,5806,6636,7766,8596,9917,0797,1967,3167,4887,6878,2158,4528,9149,1279,3499,5779,7429,96010,16810,38210,62211,03611,35011,50411,86911,82111,0509,5197,6926,0215,3574,5253,3978446124703402202202,3202,0601,8201,8201,8502,130000
       Property Plant Equipment 
0
0
0
200
1,570
1,560
1,600
1,870
2,150
220
220
340
470
612
844
3,397
4,525
5,357
6,021
7,692
9,519
10,554
11,498
11,508
11,211
11,090
10,863
10,584
10,346
10,135
9,930
9,714
9,552
9,327
9,109
8,906
8,450
8,215
7,687
7,488
7,316
7,196
7,079
6,957
6,842
6,724
6,595
5,520
5,105
5,014
4,928
5,617
5,536
5,621
5,517
5,421
5,251
4,458
4,388
4,384
4,316
4,227
198
601
615
566
549
955
1,360
1,347
1,319
1,358
1,449
1,425
1,294
1,290
1,235
1,163
1,091
1,006
142
121
100
79
66
56
46
38
38
0
0
0
0
0
0
0
74
63
51
39
26
13
0
72
58
44
30
15
1530445872013263951637400000003838465666791001211421,0061,0911,1631,2351,2901,2941,4251,4491,3581,3191,3471,3609555495666156011984,2274,3164,3844,3884,4585,2515,4215,5175,6215,5365,6174,9285,0145,1055,5206,5956,7246,8426,9577,0797,1967,3167,4887,6878,2158,4508,9069,1099,3279,5529,7149,93010,13510,34610,58410,86311,09011,21111,50811,49810,5549,5197,6926,0215,3574,5253,3978446124703402202202,1501,8701,6001,5601,570200000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,084
9,084
9,084
9,084
0
0
0
0
1,130
1,130
1,130
8,782
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000008,7821,1301,1301,13000009,0849,0849,0849,084000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
60
240
230
220
190
170
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,145
4,055
3,965
3,875
2,702
2,642
0
0
2,630
2,844
3,785
3,709
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000003,7093,7852,8442,630002,6422,7023,8753,9654,0554,14500000000000000000000000000000000000000000017019022023024060000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37
24
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000242437000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
3,260
7,110
6,620
8,150
8,320
8,270
4,000
4,300
720
423
318
480
1,246
1,286
1,105
1,964
3,207
2,674
7,515
7,100
10,917
9,485
5,847
4,201
10,410
10,277
10,486
9,251
8,871
8,546
11,818
14,150
12,024
10,995
10,010
9,897
8,429
8,210
4,720
4,648
5,868
5,921
7,765
8,211
7,025
6,663
6,350
5,014
18,228
17,053
7,372
6,867
7,297
7,494
8,513
7,702
11,797
11,702
12,358
17,212
17,258
17,237
13,530
10,354
12,338
16,104
8,438
7,800
12,890
17,967
14,640
17,511
17,799
17,275
15,607
15,947
12,216
4,511
2,243
2,504
2,335
1,732
1,938
1,451
1,188
9,307
5,340
5,863
11,103
7,406
4,053
3,186
14,922
16,610
7,611
8,034
26,177
25,056
26,440
32,629
33,357
44,299
59,069
36,630
38,928
38,92836,63059,06944,29933,35732,62926,44025,05626,1778,0347,61116,61014,9223,1864,0537,40611,1035,8635,3409,3071,1881,4511,9381,7322,3352,5042,2434,51112,21615,94715,60717,27517,79917,51114,64017,96712,8907,8008,43816,10412,33810,35413,53017,23717,25817,21212,35811,70211,7977,7028,5137,4947,2976,8677,37217,05318,2285,0146,3506,6637,0258,2117,7655,9215,8684,6484,7208,2108,4299,89710,01010,99512,02414,15011,8188,5468,8719,25110,48610,27710,4104,2015,8479,48510,9177,1007,5152,6743,2071,9641,1051,2861,2464803184237204,3004,0008,2708,3208,1506,6207,1103,260000
   > Total Current Liabilities 
0
0
0
3,260
6,240
5,790
7,350
7,590
7,610
4,000
4,300
720
423
318
480
1,246
1,286
1,105
1,360
2,482
2,026
2,435
1,838
5,484
5,407
2,689
1,942
3,074
3,130
3,500
2,417
2,070
1,849
1,887
5,409
7,901
6,768
8,920
8,822
7,371
7,193
3,707
3,631
2,330
2,322
2,047
2,510
1,400
962
1,020
453
14,175
12,008
2,354
1,868
2,317
2,538
3,677
2,888
10,021
9,893
10,873
14,780
10,766
10,169
11,003
8,400
11,760
14,580
1,181
6,386
11,306
7,158
4,974
6,855
15,758
13,248
13,265
12,606
11,294
2,590
1,844
1,814
1,583
1,690
1,903
1,425
1,172
9,307
5,340
5,538
10,778
7,206
3,706
2,839
7,429
13,338
7,595
8,034
8,287
10,130
14,627
21,887
25,158
39,200
56,112
35,327
38,928
38,92835,32756,11239,20025,15821,88714,62710,1308,2878,0347,59513,3387,4292,8393,7067,20610,7785,5385,3409,3071,1721,4251,9031,6901,5831,8141,8442,59011,29412,60613,26513,24815,7586,8554,9747,15811,3066,3861,18114,58011,7608,40011,00310,16910,76614,78010,8739,89310,0212,8883,6772,5382,3171,8682,35412,00814,1754531,0209621,4002,5102,0472,3222,3303,6313,7077,1937,3718,8228,9206,7687,9015,4091,8871,8492,0702,4173,5003,1303,0741,9422,6895,4075,4841,8382,4352,0262,4821,3601,1051,2861,2464803184237204,3004,0007,6107,5907,3505,7906,2403,260000
       Short-term Debt 
0
0
0
2,570
2,830
2,420
4,650
4,700
4,160
2,410
2,980
130
0
0
0
0
0
0
219
288
295
405
502
610
1,103
639
781
899
871
810
734
644
560
465
357
3,289
3,129
6,063
6,020
4,873
4,904
1,936
1,968
0
0
1,000
1,000
0
0
0
0
12,154
9,924
427
428
432
248
0
0
4,004
4,000
4,000
4,000
4,362
6,090
1,412
1,441
2,600
2,659
1,181
1,203
4,779
531
919
2,683
9,475
8,746
8,070
7,372
6,650
6,650
0
0
0
0
0
2,180
0
4,458
1,105
690
963
309
722
0
2,431
2,345
55
51
1,068
4,264
7,460
10,655
11,923
11,680
12,386
15,604
14,228
14,22815,60412,38611,68011,92310,6557,4604,2641,06851552,3452,43107223099636901,1054,45802,180000006,6506,6507,3728,0708,7469,4752,6839195314,7791,2031,1812,6592,6001,4411,4126,0904,3624,0004,0004,0004,004002484324284279,92412,15400001,0001,000001,9681,9364,9044,8736,0206,0633,1293,2893574655606447348108718997816391,1036105024052952882190000001302,9802,4104,1604,7004,6502,4202,8302,570000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,180
0
0
0
0
0
0
0
0
2,431
2,296
4
0
1,030
4,238
7,447
10,655
11,865
11,620
12,340
15,573
14,213
14,21315,57312,34011,62011,86510,6557,4474,2381,030042,2962,431000000002,18000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
1,410
1,410
560
220
220
0
0
0
423
212
363
1,246
1,286
1,105
1,141
2,195
1,473
2,029
1,336
4,874
4,304
2,050
1,161
774
874
1,316
1,503
1,148
1,069
1,133
1,298
690
748
552
720
588
694
513
655
622
604
599
1,308
0
0
0
0
-25
-25
-26
-27
-31
-32
3,334
2,544
1,138
738
695
2,034
2,284
1,850
1,458
615
926
992
1,128
1,221
6,527
880
446
417
1,580
1,096
1,601
1,434
960
485
140
262
58
344
1,054
322
235
2,421
1,025
1,848
796
3,281
630
355
1,887
1,628
1,038
3,401
1,693
2,127
2,306
5,952
3,626
5,963
6,437
9,320
16,403
16,4039,3206,4375,9633,6265,9522,3062,1271,6933,4011,0381,6281,8873556303,2817961,8481,0252,4212353221,054344582621404859601,4341,6011,0961,5804174468806,5271,2211,1289929266151,4581,8502,2842,0346957381,1382,5443,334-32-31-27-26-25-2500001,3085996046226555136945887205527486901,2981,1331,0691,1481,5031,3168747741,1612,0504,3044,8741,3362,0291,4732,1951,1411,1051,2861,2463632124230002202205601,4101,4100000
       Other Current Liabilities 
0
0
0
690
2,000
1,960
2,140
2,670
3,230
1,590
1,320
590
0
106
116
0
0
0
0
0
259
0
0
0
0
0
0
1,273
1,288
1,371
180
278
220
289
172
1,136
352
116
139
217
184
128
161
755
213
142
202
1,400
952
960
443
1,928
1,943
1,846
1,332
1,706
2,126
2,941
2,471
4,698
4,965
5,747
8,143
3,584
1,725
8,070
6,299
6,434
5,475
-3,128
2,678
-226
5,566
3,452
3,748
4,566
3,307
3,344
3,800
3,684
2,105
1,704
1,552
1,513
1,346
849
1,103
937
6,886
4,315
3,690
9,982
3,925
3,076
2,484
1,062
1,440
733
657
1,598
3,739
4,861
5,280
9,609
21,557
31,700
4,063
8,297
8,2974,06331,70021,5579,6095,2804,8613,7391,5986577331,4401,0622,4843,0763,9259,9823,6904,3156,8869371,1038491,3461,5131,5521,7042,1053,6843,8003,3443,3074,5663,7483,4525,566-2262,678-3,1285,4756,4346,2998,0701,7253,5848,1435,7474,9654,6982,4712,9412,1261,7061,3321,8461,9431,9284439609521,4002021422137551611281842171391163521,1361722892202781801,3711,2881,2730000002590000011610605901,3201,5903,2302,6702,1401,9602,000690000
   > Long-term Liabilities 
0
0
0
0
870
830
800
730
660
0
0
0
0
0
0
0
0
0
604
725
648
5,080
5,262
5,433
4,078
3,159
2,259
7,336
7,147
6,986
6,835
6,802
6,697
9,931
8,740
4,123
4,228
1,090
1,075
1,058
1,017
1,014
1,017
3,538
3,599
5,718
5,702
5,626
5,701
5,330
4,561
4,053
5,045
5,018
5,000
4,980
4,956
4,836
4,815
1,777
1,809
1,485
2,432
6,492
7,068
2,527
1,954
578
1,524
7,257
1,414
1,584
10,809
9,666
10,656
2,041
4,027
2,342
3,341
922
1,921
399
690
752
42
35
26
16
6,886
4,315
325
325
200
347
347
7,493
3,272
16
0
17,890
14,926
11,813
10,742
8,199
5,099
2,957
1,303
0
01,3032,9575,0998,19910,74211,81314,92617,8900163,2727,4933473472003253254,3156,886162635427526903991,9219223,3412,3424,0272,04110,6569,66610,8091,5841,4147,2571,5245781,9542,5277,0686,4922,4321,4851,8091,7774,8154,8364,9564,9805,0005,0185,0454,0534,5615,3305,7015,6265,7025,7183,5993,5381,0171,0141,0171,0581,0751,0904,2284,1238,7409,9316,6976,8026,8356,9867,1477,3362,2593,1594,0785,4335,2625,0806487256040000000006607308008308700000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,000
4,000
20
0
0
0
3,413
3,394
1,075
1,102
0
0
0
0
4,626
4,294
3,954
7,193
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147
0
7,293
3,247
4
0
0
0
11,813
10,742
0
0
0
0
0
0000010,74211,81300043,2477,29301470000000000000000007,1933,9544,2944,62600001,1021,0753,3943,413000204,0004,000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
16
4,458
0
325
325
200
200
200
200
0
0
0
0
0
0
0
0
0
0
0
0
00000000000020020020020032532504,45816011000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
836
815
1,229
1,183
1,138
1,761
2,435
3,013
851
725
0
444
1,400
1,356
1,000
6,213
5,466
3,273
1,841
0
2,200
3,300
800
1,854
339
636
694
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000006946363391,8548003,3002,20001,8413,2735,4666,2131,0001,3561,40044407258513,0132,4351,7611,1381,1831,229815836000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-930
-1,540
-510
-1,600
-2,390
-3,080
-3,460
3,920
6,910
11,902
18,442
41,490
38,744
36,388
33,004
29,950
24,108
18,535
17,548
11,324
3,223
2,842
7,781
16,040
12,723
8,926
12,543
8,555
11,401
6,805
3,525
3,117
1,308
6,527
6,067
4,309
11,504
9,985
8,350
6,541
4,805
3,504
2,739
139
1,532
2,549
1,701
1,633
2,705
5,239
17,108
14,765
11,567
12,108
5,567
6,275
4,818
20,175
16,840
23,538
6,621
-609
13,392
11,947
10,972
8,890
11,847
11,996
1,919
1,670
-3,250
-7,911
-9,944
-6,843
-9,441
-7,537
-7,516
842
6,572
6,319
4,371
4,288
5,284
4,113
2,572
3,037
4,939
10,348
-7
6,765
3,707
6,692
2,572
24,760
82,698
72,912
57,323
45,637
26,227
7,879
-10,611
-20,658
-47,180
-30,412
-33,510
-33,510-30,412-47,180-20,658-10,6117,87926,22745,63757,32372,91282,69824,7602,5726,6923,7076,765-710,3484,9393,0372,5724,1135,2844,2884,3716,3196,572842-7,516-7,537-9,441-6,843-9,944-7,911-3,2501,6701,91911,99611,8478,89010,97211,94713,392-6096,62123,53816,84020,1754,8186,2755,56712,10811,56714,76517,1085,2392,7051,6331,7012,5491,5321392,7393,5044,8056,5418,3509,98511,5044,3096,0676,5271,3083,1173,5256,80511,4018,55512,5438,92612,72316,0407,7812,8423,22311,32417,54818,53524,10829,95033,00436,38838,74441,49018,44211,9026,9103,920-3,460-3,080-2,390-1,600-510-1,540-930000
   Common Stock
0
0
0
10
10
10
10
10
10
10
20
20
19
22
25
25
25
25
26
26
26
28
28
28
29
30
39
40
40
46
46
52
52
52
54
56
66
67
67
80
81
83
83
83
83
84
84
84
84
86
91
105
127
13
13
19
20
20
21
21
27
27
30
30
30
37
38
38
38
38
40
44
50
50
50
50
62
62
8
8
8
13
15
15
16
23
28
28
20
21
27
27
44
44
53
54
78
102
102
105
105
106
107
107
122
124
159
10
101591241221071071061051051021027854534444272721202828231615151388862625050505044403838383837303030272721212020191313127105918684848484838383838180676766565452525246464040393029282828262626252525252219202010101010101010000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-212,445
-214,666
-219,357
-224,070
-228,997
-231,491
-251,128
-259,801
-263,736
-266,721
0
-271,328
-269,451
-272,564
-289,852
-296,264
-301,509
-306,543
-308,875
0
-314,718
-316,009
-316,308
-308,235
-309,709
-313,541
-315,987
-318,258
-320,535
-323,373
-325,229
-40,318
-42,181
-45,402
-56,061
-60,893
-64,622
0
-75,162
-94,278
-103,136
-113,951
0
0
176,483
196,087
-214,744
-228,175
-257,671
0
0
00-257,671-228,175-214,744196,087176,48300-113,951-103,136-94,278-75,1620-64,622-60,893-56,061-45,402-42,181-40,318-325,229-323,373-320,535-318,258-315,987-313,541-309,709-308,235-316,308-316,009-314,7180-308,875-306,543-301,509-296,264-289,852-272,564-269,451-271,3280-266,721-263,736-259,801-251,128-231,491-228,997-224,070-219,357-214,666-212,445000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-100
-120
-60
-20
-420
-260
0
0
-20
-2
-17
-33
-109
-226
-207
-154
-110
-128
-787
-211
-199
-8
-24
-26
-19
-11
-5
4
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-4,198
-4,198
-4,198
-4,198
-4,611
-4,611
0
0
-4,834
-4,834
0
0
-5,452
-5,452
0
0
-3,552
-3,552
0
37
641
719
-132
-152
-156
-156
0
0
-325
-325
0
0
-585
-585
0
0
-818
-818
0
0
-442
-442
0
0
-483
-483
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000-483-48300-442-44200-818-81800-585-58500-325-32500-156-156-152-132719641370-3,552-3,55200-5,452-5,45200-4,834-4,83400-4,611-4,611-4,198-4,198-4,198-4,198-10-10-10-10-10-10-10-10-10-10-10-104-5-11-19-26-24-8-199-211-787-128-110-154-207-226-109-33-17-2-2000-260-420-20-60-120-100000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
217,993
220,920
224,154
244,219
245,810
254,963
257,078
258,443
277,091
278,630
0
280,180
281,260
284,520
291,727
297,884
298,209
298,582
298,881
0
305,215
308,464
308,784
309,069
316,268
319,845
320,343
322,530
325,796
327,458
327,773
43,335
47,099
55,723
56,027
67,614
68,285
0
77,680
118,960
185,732
186,761
0
0
202,604
203,859
204,026
207,395
210,367
0
0
00210,367207,395204,026203,859202,60400186,761185,732118,96077,680068,28567,61456,02755,72347,09943,335327,773327,458325,796322,530320,343319,845316,268309,069308,784308,464305,2150298,881298,582298,209297,884291,727284,520281,260280,1800278,630277,091258,443257,078254,963245,810244,219224,154220,920217,993000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
7,340
7,750
9,920
10,070
10,980
10,900
11,160
19,130
22,360
28,733
37,782
62,778
63,281
64,138
64,342
64,744
65,320
65,326
71,277
71,929
72,687
75,756
84,667
96,100
100,515
100,699
108,358
109,086
117,103
117,131
111,430
116,219
118,282
126,945
131,897
131,966
140,783
141,302
141,657
141,910
143,438
143,779
144,642
145,081
145,748
141,469
142,045
143,163
179,167
186,081
202,344
202,606
218,240
216,740
217,993
220,920
227,706
244,219
245,810
254,999
256,719
258,162
277,223
278,782
279,156
280,180
281,260
284,520
292,052
297,884
298,209
298,582
299,466
304,475
305,215
308,464
309,602
309,069
316,268
319,845
320,785
322,530
325,796
327,458
328,256
43,335
47,099
55,723
56,027
67,614
68,285
75,351
77,680
118,960
185,732
186,761
198,428
200,743
202,604
203,859
204,026
207,395
210,367
216,602
219,106
219,106216,602210,367207,395204,026203,859202,604200,743198,428186,761185,732118,96077,68075,35168,28567,61456,02755,72347,09943,335328,256327,458325,796322,530320,785319,845316,268309,069309,602308,464305,215304,475299,466298,582298,209297,884292,052284,520281,260280,180279,156278,782277,223258,162256,719254,999245,810244,219227,706220,920217,993216,740218,240202,606202,344186,081179,167143,163142,045141,469145,748145,081144,642143,779143,438141,910141,657141,302140,783131,966131,897126,945118,282116,219111,430117,131117,103109,086108,358100,699100,51596,10084,66775,75672,68771,92971,27765,32665,32064,74464,34264,13863,28162,77837,78228,73322,36019,13011,16010,90010,98010,0709,9207,7507,340000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,203
Cost of Revenue-57
Gross Profit2,1462,146
 
Operating Income (+$)
Gross Profit2,146
Operating Expense-42,645
Operating Income-40,499-40,499
 
Operating Expense (+$)
Research Development30,117
Selling General Administrative12,585
Selling And Marketing Expenses0
Operating Expense42,64542,702
 
Net Interest Income (+$)
Interest Income198
Interest Expense-75
Other Finance Cost-0
Net Interest Income123
 
Pretax Income (+$)
Operating Income-40,499
Net Interest Income123
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,882-43,116
EBIT - interestExpense = -40,574
-37,882
-37,807
Interest Expense75
Earnings Before Interest and Taxes (EBIT)-40,499-37,807
Earnings Before Interest and Taxes (EBITDA)-40,442
 
After tax Income (+$)
Income Before Tax-37,882
Tax Provision-0
Net Income From Continuing Ops-37,882-37,882
Net Income-37,882
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses42,702
Total Other Income/Expenses Net2,617-123
 

Technical Analysis of Seelos Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Seelos Therapeutics Inc. The general trend of Seelos Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Seelos Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Seelos Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.3676 < 0.68 < 0.7071.

The bearish price targets are: .

Tweet this
Seelos Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Seelos Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Seelos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Seelos Therapeutics Inc. The current macd is -0.12914873.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Seelos Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Seelos Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Seelos Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Seelos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSeelos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Seelos Therapeutics Inc. The current adx is 36.83.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Seelos Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Seelos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Seelos Therapeutics Inc. The current sar is 0.49474918.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Seelos Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Seelos Therapeutics Inc. The current rsi is 26.09. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Seelos Therapeutics Inc Daily Relative Strength Index (RSI) ChartSeelos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Seelos Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Seelos Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Seelos Therapeutics Inc Daily Stochastic Oscillator ChartSeelos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Seelos Therapeutics Inc. The current cci is -162.34287899.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Seelos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSeelos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Seelos Therapeutics Inc. The current cmo is -58.3862718.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Seelos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSeelos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Seelos Therapeutics Inc. The current willr is -95.48410405.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Seelos Therapeutics Inc Daily Williams %R ChartSeelos Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Seelos Therapeutics Inc.

Seelos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Seelos Therapeutics Inc. The current atr is 0.0797467.

Seelos Therapeutics Inc Daily Average True Range (ATR) ChartSeelos Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Seelos Therapeutics Inc. The current obv is -112,691,596.

Seelos Therapeutics Inc Daily On-Balance Volume (OBV) ChartSeelos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Seelos Therapeutics Inc. The current mfi is 15.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Seelos Therapeutics Inc Daily Money Flow Index (MFI) ChartSeelos Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Seelos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Seelos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Seelos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.088
Ma 20Greater thanMa 500.492
Ma 50Greater thanMa 1000.766
Ma 100Greater thanMa 2001.088
OpenGreater thanClose0.340
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Seelos Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Seelos Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Seelos Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Seelos Therapeutics Inc

I send you an email if I find something interesting about Seelos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Seelos Therapeutics Inc.

Receive notifications about Seelos Therapeutics Inc in your mailbox!